ClinicalTrials.gg
CompletedNCT06864143Updated Oct 20, 2025

A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

A Phase 2 interventional study of mRNA-1083 Composition 1 Dose A Lot A and mRNA-1083 Composition 1 Dose A Lot B in Influenza and SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 17 sites in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-20.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,320
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Influenza, Human by Moderna, Inc. — 2 open to participants now, 3 under way, 1 of them phase 3. Influenza, Human · Moderna, Inc..

Enrollment
10th of 23
1,320 · median 885
Started
2025
the only one that year
Phase 2
4 of 23
none open now
Registered
20th of 23
by date

Among the 23 studies in Influenza, Human by Moderna, Inc., this one is the 10th largest by enrollment, is the only one that started in 2025, is one of 4 in phase 2, and was the 20th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 23 studies in Influenza, Human by Moderna, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Influenza, Human by Moderna, Inc., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age.

03

Conditions studied

  • Influenza
  • SARS-CoV-2

Keywords

  • Influenza
  • SARS-CoV-2
  • mRNA-1083
  • COVID-19
  • Messenger RNA
  • Moderna
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medically stable.
  • Participants who could become pregnant: negative pregnancy test and for at least 28 days prior to Day 1 and for at least 90 days after the study intervention administration.
  • Have received ≥2 coronavirus disease 2019 (COVID-19) vaccines, with the last COVID-19 vaccine administered >150 days prior to Day 1.

Exclusion criteria

Exclusion Criteria:

  • History of a diagnosis or condition that is clinically unstable or may affect participant safety, assessment of study endpoints, assessment of immune response, or adherence to study procedures.
  • Tested positive for influenza by local health authority-approved testing methods within 150 days prior to Day 1.
  • History of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 150 days prior to Day 1.
  • Received systemic treatment, including long-acting biological therapies that affect immune responses (eg, infliximab), within 180 days prior to Day 1 or plans to do so during the study.
  • Received or plans to receive any vaccine authorized or approved by a local health agency within 28 days prior to Day 1 or plans to do so within 28 days post study injection.
  • Received a licensed seasonal influenza vaccine within 150 days prior to Day 1.
  • Received a licensed/authorized COVID-19 vaccine within 150 days prior to Day 1.
  • Received any influenza vaccine, investigational COVID-19 vaccine, or investigational combination vaccine for influenza and COVID-19 within 12 months prior to Day 1.
  • Participated in a clinical study with investigational treatment within 90 days prior to Day 1 (Baseline).

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,320 participants (actual)

Study arms

  • Experimental
    mRNA-1083 Composition 1 Dose A Lot A

    Participants will receive single intramuscular (IM) injection of mRNA-1083 Composition 1 at Dose Level A Lot A on Day 1.

    Biological: mRNA-1083 Composition 1 Dose A Lot A

  • Experimental
    mRNA-1083 Composition 1 Dose A Lot B

    Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level A Lot B on Day 1.

    Biological: mRNA-1083 Composition 1 Dose A Lot B

  • Experimental
    mRNA-1083 Composition 1 Dose B

    Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level B on Day 1.

    Biological: mRNA-1083 Composition 1 Dose B

  • Experimental
    mRNA-1083 Composition 1 Dose C

    Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level C on Day 1.

    Biological: mRNA-1083 Composition 1 Dose C

  • Experimental
    mRNA-1083 Composition 2 Dose A

    Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level A on Day 1.

    Biological: mRNA-1083 Composition 2 Dose A

  • Experimental
    mRNA-1083 Composition 2 Dose B

    Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level B on Day 1.

    Biological: mRNA-1083 Composition 2 Dose B

  • Experimental
    mRNA-1083 Composition 3 Dose A

    Participants will receive single IM injection of mRNA-1083 Composition 3 at Dose Level A on Day 1.

    Biological: mRNA-1083 Composition 3 Dose A

  • Experimental
    mRNA-1083 Composition 3 Dose B

    Participants will receive single IM injection of mRNA-1083 Composition 3 at Dose Level B on Day 1.

    Biological: mRNA-1083 Composition 3 Dose B

  • Active comparator
    Influenza Vaccine

    Participants will receive single IM injection of Influenza Vaccine on Day 1.

    Biological: Influenza Vaccine

  • Active comparator
    COVID-19 Vaccine

    Participants will receive single IM injection of COVID-19 Vaccine on Day 1.

    Biological: COVID-19 Vaccine

  • Active comparator
    Investigational Influenza Vaccine

    Participants will receive single IM injection of Investigational Influenza Vaccine on Day 1.

    Biological: Investigational Influenza Vaccine

  • Active comparator
    Investigational COVID-19 Vaccine Lot A

    Participants will receive single IM injection of Investigational COVID-19 Vaccine Lot A on Day 1.

    Biological: Investigational COVID-19 Vaccine Lot A

  • Active comparator
    Investigational COVID-19 Vaccine Lot B

    Participants will receive single IM injection of Investigational COVID-19 Vaccine Lot B on Day 1.

    Biological: Investigational COVID-19 Vaccine Lot B

Interventions

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titer (GMT) as Measured by Hemagglutination Inhibition (HAI) Assay for Influenza

    Time frame: Day 29

  2. Geometric Mean Concentration (GMC) as Measured by Pseudovirus Neutralization Assay (PsVNA) for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

    Time frame: Day 29

  3. Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

    Time frame: Day 1 through 7 days after study injection

  4. Number of Participants With Unsolicited Adverse Events (AEs)

    Time frame: Day 1 through 28 days after study injection

  5. Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation From the Study

    Time frame: Day 1 through Day 181

Secondary outcomes

  1. Geometric Mean Fold-Rise (GMFR) of Antibodies for Influenza as Measured by HAI Assay

    Time frame: Baseline (Day 1), Day 29

  2. GMFR of Antibodies for SARS-CoV-2 as Measured by PsVNA

    Time frame: Baseline (Day 1), Day 29

  3. Influenza: Percentage of Participants with Seroconversion as Measured by HAI Assay

    Seroconversion is defined as postinjection level ≥1:40 if baseline is \<1:10 or at least a 4-fold rise if baseline is ≥1:10 in HAI antibody titer.

    Time frame: Baseline (Day 1) to Day 29

  4. SARS-CoV-2: Percentage of Participants with Seroresponse as Measured by PsVNA

    Seroresponse is defined as PsVNA concentration change from preinjection baseline below the lower limit of quantification (LLOQ) to postinjection ≥4×LLOQ, or at least a 4-fold rise if baseline is ≥LLOQ.

    Time frame: Baseline (Day 1) to Day 29

07

Study locations

17 sites
  • Headlands Research Scottsdale
    Scottsdale, Arizona 85260, United States
  • Artemis Research (Headlands)
    San Diego, California 92103, United States
  • Clinical Research Atlanta (Headlands)
    Stockbridge, Georgia 30281, United States
  • Velocity Clinical Research, Boise
    Meridian, Idaho 83642, United States
  • DM Clinical Research - Chicago
    Melrose Park, Illinois 60160, United States
  • Velocity Clinical Research, Lafayette
    Lafayette, Louisiana 70809, United States
  • Velocity Clinical Research, Rockville
    Rockville, Maryland 20854, United States
  • DM Clinical Research - Boston
    Brookline, Massachusetts 02446, United States
  • DM Clinical Research - Detroit
    Southfield, Michigan 48076, United States
  • Velocity Clinical Research, Norfolk
    Norfolk, Nebraska 68701, United States
  • Trial Management Associates, LLC
    Wilmington, North Carolina 28403, United States
  • Velocity Clinical Research, Cincinnati, Mt. Auburn
    Cincinnati, Ohio 45219, United States
  • Velocity Clinical Research, Cincinnati, Springdale
    Cincinnati, Ohio 45246, United States
  • DM Clinical Research - Philadelphia
    Philadelphia, Pennsylvania 19107, United States
  • Trial Management Associates, LLC
    Myrtle Beach, South Carolina 29572, United States
  • DM Clinical Research - Bellaire
    Houston, Texas 77081, United States
  • DM Clinical Research - Tomball
    Tomball, Texas 77375, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Oct 2025, 7 months.

Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 7 months is close to that.

Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2025
First posted
Mar 7, 2025
StartActual
Mar 7, 2025
Primary completionActual
Oct 13, 2025
CompletionActual
Oct 13, 2025
Last update
Oct 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06864143
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Mar 7, 2025
Start date
Mar 7, 2025
Primary completion
Oct 13, 2025
Completion
Oct 13, 2025
Last update
Oct 20, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MRNA-1083

Start the discussion